This grant aims to address critical gaps in understanding the impact of HIV and antiretroviral therapy (ART) on placental health and maternal outcomes, particularly when compounded by substance use. Despite ART’s success in preventing vertical HIV transmission, it’s linked to adverse birth outcomes like preterm birth and stillbirth. Optimal placental development is crucial for healthy pregnancies. This funding supports research to investigate how HIV/ART exposure affects the placenta, with an emphasis on pregnant individuals with co-occurring substance use, where data is extremely limited. The ultimate goal is to improve maternal and fetal well-being in this vulnerable population. The closing date for applications is November 15, 2024.
Opportunity ID: 350786
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-25-021 |
| Funding Opportunity Title: | Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 30, 2023 |
| Last Updated Date: | Oct 30, 2023 |
| Original Closing Date for Applications: | Nov 15, 2024 |
| Current Closing Date for Applications: | Nov 15, 2024 |
| Archive Date: | Dec 21, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Small businesses Independent school districts For profit organizations other than small businesses Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death. Optimal development and functioning of the placenta are key factors in maintenance of pregnancy and positively corelate with maternal and fetal outcomes. Despite this, there is considerable paucity of data on the impact of HIV/ART exposure on the placenta. Even less is known on the impact of HIV/ART exposure on the placenta in pregnant individuals with substance use/misuse. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-021.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 350786 Full Announcement-RFA-DA-25-021 -> RFA-DA-25-021-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00283639 | Oct 15, 2024 | Nov 15, 2024 | View |
Package 1
Mandatory forms
350786 RR_SF424_5_0-5.0.pdf
350786 PHS398_CoverPageSupplement_5_0-5.0.pdf
350786 RR_OtherProjectInfo_1_4-1.4.pdf
350786 PerformanceSite_4_0-4.0.pdf
350786 RR_KeyPersonExpanded_4_0-4.0.pdf
350786 PHS398_ResearchPlan_5_0-5.0.pdf
350786 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
350786 RR_Budget_3_0-3.0.pdf
350786 RR_SubawardBudget30_3_0-3.0.pdf
350786 PHS398_ModularBudget_1_2-1.2.pdf
350786 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
